Menu Search Account

LegiStorm

Get LegiStorm App Visit Product Demo Website
» Get LegiStorm App
» Get LegiStorm Pro Free Demo

Regulation of Plant-Based Pharmaceuticals (CRS Report for Congress)

Premium   Purchase PDF for $24.95 (6 pages)
add to cart or subscribe for unlimited access
Release Date March 8, 2005
Report Number RS21418
Report Type Report
Authors Geoffrey S. Becker, Resources, Science, and Industry Division; and Donna Vogt, Domestic Social Policy Division
Source Agency Congressional Research Service
Summary:

Among many genetically engineered crops being developed are a number modified to produce pharmaceutical compounds (none yet commercialized). Proponents say proteins from such plants might be used, for example, to vaccinate against and/or treat various cancers; infectious, cardiovascular, and nervous system diseases; metabolic disorders; and biowarfare agents. Farmers might benefit economically from increased demand for new crop products. But critics see risks, such as potential environmental, food safety, and trade problems. Among the issues is whether the current system for regulating biotechnologyshared by several federal agenciesis adequate and, if not, what types of changes are needed.